Home | Contact | Directions
Bookmark and Share

Newsroom

Constellation’s CEO Keith Dionne to present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco. 7:30 am on January 11th 2016

Posted in Newsroom

CAMBRIDGE, January 5, 2016.  Constellation’s CEO, Keith Dionne, will be presenting a corporate update at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 7:30 a.m. Pacific at the Westin St. Francis Hotel in San Francisco. The

Read more »

Constellation Pharmaceuticals, Inc. Raises $55 Million in Mezzanine Financing

Posted in Newsroom

Funding Supports Advancement of Pipeline and Epigenetics Platform

CAMBRIDGE, Massachusetts, December 9, 2015 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced the successful completion of a $55 million mezzanine round of financing. The …

Read more »

Constellation Pharmaceuticals Initiates Clinical Development of CPI-1205, a Novel Inhibitor of EZH2, in Patients with Lymphoma

Posted in Constellation in the News, Newsroom

Second Constellation Pipeline Program to Enter the Clinic

CAMBRIDGE, Mass. –April 28, 2015 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of chromatin biology, today announced that it has initiated a Phase 1 clinical trial of …

Read more »

Development of methyl isoxazoleazepines as inhibitors of BET

Posted in Constellation in the News, Newsroom

Our paper “Development of methyl isoxazoleazepines as inhibitors of BET” is now available in Bioorganic & Medicinal Chemistry Letters.

View full paper here.

 …

Read more »

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Posted in Constellation in the News, Newsroom

This paper, by Dr. Eugenia Xu and colleagues from the Sackler Foundation and Robert Wood Johnson Medical School and scientists from Constellation Pharmaceuticals, is now available in the open-access journal Cell Death and Disease.

View full paper here

Read more »

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Posted in Constellation in the News, Newsroom

In this paper, Dr. Gael Roué and his colleagues at the IDIBAPS in Barcelona and scientists from Constellation Pharmaceuticals presented evidence of a synergistic anti-tumor activity of lenalidomide in combination with a BET inhibitor in bortezomib-resistant mantle cell lymphoma cell …

Read more »

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Posted in Constellation in the News, Newsroom

Our paper “EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation” is now available in Cell Press, Chemistry and Biology.

View full paper here

Read more »

Constellation meets contractual milestones and receives balance of $15 million loan

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has secured a $15 million senior secured loan with Oxford Finance and Silicon Valley Bank.  Constellation had already drawn down $5 million from this facility, which was originally closed back in June of 2013 and,

Read more »

A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation

Posted in Constellation in the News, Newsroom

Our paper “A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation” is now available in American Chemical Society, Organic Letters.

 

View full paper here

Read more »

Constellation Expands Clinical Studies of CPI-0610

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has initiated two additional clinical studies of its lead BET Inhibitor, CPI-0610.  CPI-0610 has been progressing in a Phase 1 clinical trial in patients with lymphoma since September of 2013.  As that trial continues, two …

Read more »

next »